About

Science

Pipeline

Investor Information

Contact Us

Investor Information

Investor Information

Press Releases

Jul 20, 2020 7:00 AM EDT Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Jul 15, 2020 7:00 AM EDT Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Jul 6, 2020 8:00 AM EDT Can-Fite Announces $3.4 Million Registered Direct Offering
Jun 30, 2020 7:00 AM EDT Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Jun 10, 2020 8:00 AM EDT Can-Fite Announces $8.0 Million Registered Direct Offering
Jun 9, 2020 7:00 AM EDT Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.
Jun 8, 2020 7:25 AM EDT Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020
Jun 4, 2020 7:14 AM EDT Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Jun 3, 2020 7:00 AM EDT Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th
Jun 1, 2020 7:00 AM EDT Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update

<< Previous
1
2
3
4
5
6
7
8
9
10
...30
Next >>

Show All